Copyright
©The Author(s) 2024.
World J Cardiol. May 26, 2024; 16(5): 282-292
Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.282
Published online May 26, 2024. doi: 10.4330/wjc.v16.i5.282
Total | Statin therapy | P value | ||
Not on recommended dose | On recommended dose | |||
Total | 195 | 22 (11.3) | 173 (88.7) | - |
Gender | ||||
Male | 139 (71.3) | 15 (68.2) | 124 (71.7) | 0.733 |
Female | 56 (28.7) | 7 (31.8) | 49 (28.3) | |
Age (mean ± SD, yr) | 57.1 ± 10.2 | 57.8 ± 11.6 | 57 ± 10 | 0.728 |
≤ 40 | 11 (5.6) | 2 (9.1) | 9 (5.2) | 0.558 |
41-65 | 150 (76.9) | 15 (68.2) | 135 (78) | |
> 65 | 34 (17.4) | 5 (22.7) | 29 (16.8) | |
Weight (mean ± SD, kg) | 73.4 ± 14.7 | 76.6 ± 15.2 | 72.9 ± 14.6 | 0.268 |
Height (mean ± SD, cm) | 155.5 ± 7.7 | 159.9 ± 7.5 | 154.9 ± 7.5 | 0.004 |
Body mass index (mean ± SD, kg/m2) | 30.4 ± 5.8 | 30.2 ± 6.6 | 30.4 ± 5.8 | 0.857 |
Underweight (< 18.5) | 1 (0.5) | 0 (0) | 1 (0.6) | 0.185 |
Healthy weight (18.5-22.9) | 16 (8.2) | 4 (18.2) | 12 (6.9) | |
Above ideal range (≥ 23) | 178 (91.3) | 18 (81.8) | 160 (92.5) | |
Waist circumference (mean ± SD, cm) | 97.2 ± 8.8 | 101.5 ± 11.7 | 96.7 ± 8.2 | 0.016 |
DM | 82 (42.1) | 11 (50) | 71 (41) | 0.423 |
Duration of DM (mean ± SD) | 9.1 ± 5.3 | 9.5 ± 6.2 | 9.1 ± 5.2 | 0.832 |
Well controlled | 13 (15.9) | 3 (27.3) | 10 (14.1) | 0.265 |
HTN | 100 (51.3) | 12 (54.5) | 88 (50.9) | 0.745 |
Duration of HTN (mean ± SD) | 8.1 ± 4.4 | 6.9 ± 3.4 | 8.2 ± 4.5 | 0.342 |
Well controlled | 54 (54) | 11 (91.7) | 43 (48.9) | 0.005 |
Tobacco | 83 (42.6) | 6 (27.3) | 77 (44.5) | 0.124 |
Duration of tobacco use (mean ± SD) | 19.1 ± 9.1 | 15.4 ± 8.2 | 19.4 ± 9.2 | 0.296 |
Chewing | 6 (7.2) | 2 (33.3) | 4 (5.2) | 0.073 |
Chewing, smoking | 6 (7.2) | 0 (0) | 6 (7.8) | |
Smoking | 71 (85.5) | 4 (66.7) | 67 (87) | |
Family history of coronary artery diseases | 101 (51.8) | 17 (77.3) | 84 (48.6) | 0.011 |
AMI | ||||
STEMI | 117 (60) | 15 (68.2) | 102 (59) | 0.406 |
NSTEMI | 78 (40) | 7 (31.8) | 71 (41) | |
Duration science first event of AMI (month) | 36 (10-48) | 36 (10-72) | 30 (10-48) | 0.299 |
Number of hospital admissions (in last 12 months) | ||||
0 | 167 (85.6) | 15 (68.2) | 152 (87.9) | 0.001 |
1 | 23 (11.8) | 4 (18.2) | 19 (11) | |
2 | 5 (2.6) | 3 (13.6) | 2 (1.2) | |
Lipid profile advised after AMI | 27 (13.8) | 6 (27.3) | 21 (12.1) | 0.053 |
Are you taken statins after 1st event of AMI? | 185 (94.9) | 12 (54.5) | 173 (100) | < 0.001 |
Duration [median (IQR), month] | 24 (9-48) | 26 (6.5-66) | 24 (10-48) | 0.818 |
What is the dose of statin you are taking? | ||||
Rosuvastatin | 179 (91.8) | 7 (31.8) | 172 (99.4) | - |
Not taking | 16 (8.2) | 15 (68.2) | 1 (0.6) | < 0.001 |
10 mg | 7 (3.6) | 7 (31.8) | 0 (0) | |
20 mg | 172 (88.2) | 0 (0) | 172 (99.4) | |
Atervastatin | 5 (2.6) | 4 (18.2) | 1 (0.6) | - |
Not taking | 190 (97.4) | 18 (81.8) | 172 (99.4) | < 0.001 |
20 mg | 4 (2.1) | 4 (18.2) | 0 (0) | |
40 mg | 1 (0.5) | 0 (0) | 1 (0.6) | |
Simvastatin | 1 (0.5) | 1 (4.5) | 0 (0) | - |
Not taking | 194 (99.5) | 21 (95.5) | 173 (100) | 0.005 |
10 mg | 1 (0.5) | 1 (4.5) | 0 (0) | |
Did you ever lipid profile get done before AMI event? | 4 (2.1) | 1 (4.5) | 3 (1.7) | 0.381 |
Total cholesterol (last lipid profile) | ||||
Available | 191 (97.9) | 22 (100) | 169 (97.7) | - |
Level (mean ± SD) | 143.1 ± 38.7 | 143 ± 35.6 | 143.1 ± 39.2 | 0.986 |
Level [median (IQR)] | 140 (115-165) | 136 (115-165) | 144 (115-163) | 0.818 |
Target total cholesterol (< 160) | 137 (71.7) | 16 (72.7) | 121 (71.6) | 0.912 |
LDL-cholesterol (last lipid profile) | ||||
Available | 191 (97.9) | 21 (95.5) | 170 (98.3) | - |
Level (mean ± SD) | 91.7 ± 34.8 | 94.7 ± 42.5 | 91.3 ± 33.8 | 0.676 |
Level [median (IQR)] | 88 (66-110) | 83 (65-94) | 88.5 (67-110) | 0.989 |
Target LDL cholesterol (< 55) | 22 (11.5) | 2 (9.5) | 20 (11.8) | 0.762 |
HDL-cholesterol (last lipid profile) | ||||
Available | 192 (98.5) | 22 (100) | 170 (98.3) | - |
Level (mean ± SD) | 40.9 ± 8.7 | 41.2 ± 10 | 40.8 ± 8.6 | 0.846 |
Level [median (IQR)] | 42 (36-45) | 42.5 (37-49) | 41.5 (36-45) | 0.466 |
Triglycerides (last lipid profile) | ||||
Available | 165 (84.6) | 17 (77.3) | 148 (85.5) | - |
Level (mean ± SD) | 167.6 ± 76.4 | 185.4 ± 125 | 165.5 ± 69.1 | 0.311 |
Level [median (IQR)] | 150 (123-190) | 152 (125-167)] | 150 (123-190) | 0.782 |
Were you taken statins before 1st event of AMI? | 3 (1.5) | 0 (0) | 3 (1.7) | 0.534 |
Duration [median (IQR), month] | 36 (12-48) | - | 36 (12-48) | - |
History of subsequent ACS event | 16 (8.2) | 3 (13.6) | 13 (7.5) | 0.324 |
Compliant to the statin therapy | 179 (91.8) | 12 (54.5) | 167 (96.5) | < 0.001 |
If no what are the reasons? | ||||
Affordability | 15 (7.7) | 9 (40.9) | 6 (3.5) | < 0.001 |
Dizziness | 1 (0.5) | 1 (4.5) | 0 (0) |
- Citation: Rauf R, Soomro MI, Khan MN, Kumar M, Soomro NA, Kazmi KA. Assessment of post-myocardial infarction lipid levels and management: Results from a tertiary care hospital of Pakistan. World J Cardiol 2024; 16(5): 282-292
- URL: https://www.wjgnet.com/1949-8462/full/v16/i5/282.htm
- DOI: https://dx.doi.org/10.4330/wjc.v16.i5.282